Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (DE:22UA)
XETRA:22UA
Holding DE:22UA?
Track your performance easily
22UA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€69.70 - €118.80
Previous Close€108.5
Volume40.01K
Average Volume (3M)39.46K
Market Cap
€25.97B
Enterprise Value€9.64B
Total Cash (Recent Filing)€16.55B
Total Debt (Recent Filing)€219.10M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Mar 10, 2025EPS Estimate
€0.48Last Dividend Ex-Date
Jun 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-1.96
Shares Outstanding237,725,735
10 Day Avg. Volume34,949
30 Day Avg. Volume39,461
Standard Deviation0.18
R-Squared0.01
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.27
Price to Sales (P/S)6.32
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€136.10Price Target Upside25.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
BioNTech SE News
PremiumCompany Announcements
FDA Lifts Hold on BioNTech’s Key Cancer Trial
Bulls Say, Bears Say
Bulls Say
Clinical Trials And EfficacyBNTX's PD1/VEGF bispecific BNT327 looks promising in early trials, showing superior efficacy in 6 different cancer settings compared to standard care.
Market PotentialAnalyst sees potential for the PD1/VEGF class to become the largest in immuno-oncology, even surpassing current PD(L)1s.
Pipeline And InnovationBioNTech has a vast pipeline including mRNA cancer vaccines and ADCs, providing additional upside potential beyond the current focus on COVID.
Bears Say
Clinical TrialsBioNTech announced an FDA partial clinical hold on the Ph 3 trial of gotistobart in anti-PD1 relapsed / refractory non-small cell lung cancer.
EarningsBioNTech guided to the low end of its €2.5-3.1B revenue range for FY24 due to pricing pressure and lower demand from middle and low-income countries.
Market CompetitionThere are no obvious indications of monotherapy differentiation for BioNTech’s B7-H3-targeted antibody drug conjugate, BNT324, in comparison to other B7-H3 ADCs and non-B7-H3, topo1i-based ADCs in the clinical landscape.
---
Options Prices
Currently, No data available
---
Ownership Overview
― Insiders
3.01% Mutual Funds
12.03% Other Institutional Investors
83.86% Public Companies and
Individual Investors
22UA FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was €69.70 and its highest was €118.80 in the past 12 months.
What is BioNTech SE’s market cap?
Currently, no data Available
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Mar 10, 2025 which is in 76 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Nov 04, 2024. The company reported €0.81 earnings per share for the quarter, beating the consensus estimate of -€1.534 by €2.344.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE pays a Notavailable dividend of €1.47 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is €0.48.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 237,766,240 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of €0.81 in its last earnings report, beating expectations of -€1.534. Following the earnings report the stock price went down -0.195%.
Which hedge fund is a major shareholder of BioNTech SE?
Among the largest hedge funds holding BioNTech SE’s share is PRIMECAP Management Co. It holds BioNTech SE’s shares valued at 536M.
---
BioNTech SE Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€136.10 (25.44% Upside)
€136.10 (25.44% Upside)
Blogger Sentiment
Bullish
DE:22UA Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $160.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.00%
12-Months-Change
Fundamentals
Return on Equity
-2.37%
Trailing 12-Months
Asset Growth
6.33%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.
---
22UA Company Deck
---
22UA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, driven by significant revenue growth, advancements in COVID-19 vaccines, and progress within the oncology pipeline. However, there were concerns regarding increased operating costs and contractual disputes. The financial guidance being at the lower end of the range was a noted challenge.Read More>---
22UA Stock 12 Month Forecast
Average Price Target
€136.10
▲(25.44% Upside)
Technical Analysis
Best Analysts Covering 22UA
1 Year
1 Year Success Rate
7/8 ratings generated profit
1 Year Average Return
+20.90%
reiterated a buy rating 23 days ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +20.90% per trade.
---